开发治疗肾纤维化的新型药物-猫眼课题宝

开发治疗肾纤维化的新型药物

批准号：

8780197

负责人：

ANIL K KARIHALOO

金额：

$61.63万

依托单位：

EPIGEN BIOSCIENCES, INC.

依托单位国家：

美国

项目类别：

财政年份：

2012

资助国家：

美国

项目状态：

已结题

起止时间：

2012-03-01 至 2016-08-31

来源：

https://reporter.nih.gov/project-details/8780197

关键词：

Achievement Acute Animal Model Area Back Behavior Biological Assay CYP2D6 gene CYP3A4 gene Caco-2 Cells Canis familiaris Cell model Characteristics Chronic Kidney Failure Clinical Development Diabetic Nephropathy Disease model Dose Drug Kinetics End stage renal failure Evaluation Feasibility Studies Fibrosis Goals Grant Human In Vitro Inhibitory Concentration 50 Kidney Lead Letters Liver Microsomes Lysophosphatidic Acid Receptors Medical Metabolic Modeling Mus Oral Administration Permeability Pharmaceutical Preparations Pharmacotherapy Phase Positioning Attribute Preparation Property Rattus Renal Replacement Therapy Research Safety Selection Criteria Series Signal Pathway Small Business Innovation Research Grant Streptozocin Testing Therapeutic Intervention Toxic effect Ureteral obstruction analog clinical efficacy commercialization improved in vivo lead series lipophilicity meetings mortality novel novel therapeutics pre-clinical preclinical study prevent programs public health relevance safety study scale up small molecule standard of care therapy development

项目摘要

项目成果

ANIL K KARIHALOO的其他基金

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

DESCRIPTION (provided by applicant): The ultimate goal of our project is to develop novel therapeutics effective in chronic kidney diseases that normally develop fibrosis, lead to end stage renal disease and require renal replacement therapy. This SBIR phase 2 application builds on the results obtained in phase 1 where novel and selective small molecule antagonists were discovered that prevent the progression of renal fibrosis in a unilateral ureteral obstruction (UUO) animal model. Leads identified in phase 1 will be optimized for drug-like and ADME properties. Candidate compounds meeting the selection criteria will be assessed for safety in vivo and the best compound will be examined in several different animal models of chronic kidney disease to delineate a development path in the clinical setting.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文